候选致病岛Uu146-Uu150在临床分离解脲脲原体中的检测分析  

Analysis on a putative pathogenicity island Uu146-Uu150 of Ureaplasma urealyticum in clinical isolates

作　　者：黄珺[1] 张钧[1] 宋铁军[1] 谢鑫友[1] 

机构地区：[1]浙江大学医学院附属邵逸夫医院检验科,浙江杭州310016

出　　处：《全科医学临床与教育》2013年第1期13-16,共4页Clinical Education of General Practice

基　　金：浙江省自然科学基金课题(Y2080234);浙江省卫生厅课题(2012KYA115)

摘　　要：目的探讨候选致病岛(PAI)Uu146-Uu150在解脲脲原体(Uu)致病性中的意义。方法收集临床分离的Uu101株,运用多带抗原(MBA)及Mycoplasma IST2试剂盒对其进行生物分群及药敏检测,用特异性引物扩增PAI Uu146-Uu150。结果生物1群为杭州地区Uu的主要生物群别(占70.30%);PAI的检出率为11.88%;Fisher检验结果显示,Uu生物1群PAI阳性率(7.04%)低于生物2群PAI阳性率(23.33%),差异有统计学意义(P<0.05)。结论 PAI Uu146-Uu150可能为一潜在的、与Uu生物2群相关的致病岛,但需要更多的流行病学调查和实验验证。Objective To investigate the pathogenicity significance of a putative pathogenicity island （PAI） Uu146- Uul50 in Ureaplasma urealyticum （Uu） infection. Methods Totally 101 Uu isolates were collected. Biovar-typing based on muhiplebanded antigen （MBA） genes was detected. Antimicrobial susceptibility for Uu was tested by Mycoplasma IST2 kits. PAI Uu146-Uu150 was amplified by PCR. Results Biotype 1 was the main biovar type of Uu in Hangzhou （70.30%）. The Fisher anaysis showed that the positive rate of biovar type 1 was lower than biovar type 2. The diffierence was statistically signifant （P〈0.05）. （P〈0.05）. Conclusions PAI Uu146-Uu150 is a potential pathogenicity island, which associated with biovar type 2. However, this need formulated by more experiments and epidemiological investigation.

关 键 词：解脲脲原体 候选致病岛 生物分群 

分 类 号：R446.5[医药卫生—诊断学]